IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker

References

• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12.
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Muller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumours. Acta Neuropathol 2008;116:597–602.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med. 2009;360:765–73.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and Frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 2009;118:469–74.
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe P, Kleihues H, Ohgaki H. IDH1 mutations as molecular signature and predictive value of secondary glioblastomas. Clin Cancer Res 2009;15:6002–7.
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–4.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavourable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707–18.
   PubMed Web of Science ®Google Scholar
• Kloosterhof N, Bralten LBC, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncol 2011;12:83–91.
   PubMed Web of Science ®Google Scholar
• Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 2012 Epub Ahead of Print.
   PubMedGoogle Scholar
• Watanabe T, Nobusawa P, Kleihaus H, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Path 2009;174:1149–53.
   PubMed Web of Science ®Google Scholar
• Yan H, Bigner D, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009;69: 9157–9.
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341–7.
   PubMed Web of Science ®Google Scholar
• Fu Y, Huang R, Du J, et al. Glioma-derived mutations in IDH: From mechanism to potential therapy. Biochem Biophys Res Commun 2010;397:127–30.
   PubMed Web of Science ®Google Scholar
• Combs SE, Rieken S, Wick W, et al. Prognostic Significance of IDH1 and MGMT in patients with glioblastoma: one step forward, and one step back. Rad Oncol 2011;6:115–9.
   PubMedGoogle Scholar
• Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organisation for Research and Treatment of Cancer Trial. J Neuropathol Exp Neuro 2007;6:545–51.
   Google Scholar
• Capper D, Weissert S, Balss J, et al. Characterisation of R132H mutation specific IDH1 antibody binding in brain tumours. Brain Pathol 2009;20:245–54.
   PubMedGoogle Scholar
• Weller M, Wick W, von Diemling A. Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011;59:1200–4.
   PubMedGoogle Scholar
• Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal Antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599–601.
   PubMed Web of Science ®Google Scholar
• Gravendeel LA, Kloosterhoof NK, Bralten LB, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 2010;31:E1186–99.
   PubMedGoogle Scholar
• Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009;69:9065–72.
   PubMed Web of Science ®Google Scholar
• Preusser M, Capper D, Hartmann C. IDH testing in diagnostic neuropathology: review and practical guideline article invited by Euro-CNS research committee. Clin Neuropathol 2011;30: 217–30.
   PubMedGoogle Scholar